Ephylone
Viewing r1 — May 11, 2026 — CURRENT
Back to HistoryInteractions, related substances, and reports reflect the current entry and are not shown for historical revisions.
Ephylone (N-ethylpentylone) is a synthetic stimulant of the substituted cathinone class. It is a close structural analog of pentylone, distinguished by an N-ethyl substitution that shifts its profile toward potent reuptake inhibitor. Ephylone is a monoamine reuptake inhibitor, producing its effects by blocking the recycling of dopamine, norepinephrine, and serotonin at their transporters.[1]
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
cocaine, amphetamine, MDPV +3 morecocaine, amphetamine, MDPV, methylone, mephedrone, eutylone show less
Synthesized in the 1960s at Boehringer Ingelheim as part of a cathinone analog series targeting depression, ephylone was never advanced to clinical trials.[2][3] It appeared on illicit markets in 2014 and by 2017 had become the most commonly seized synthetic cathinone in the United States.[4] It is now permanently Schedule I in the United States and Schedule II under the UN 1971 Convention on Psychotropic Substances.[5]
Subjective effects include euphoria, stimulation, wakefulness, and mild empathogenic warmth. The experience is stimulant-dominant — a surging dopaminergic energy overlaid with thin serotonergic warmth that falls well short of the emotional depth associated with MDMA.[3] Compulsive redosing, anxious overstimulation, and a prolonged dysphoric comedown are characteristic unsought effects.
Ephylone carries high dependence potential[6][7] and significant acute toxicity, with 151 overdose deaths linked to the compound in the United States between 2015 and 2018.[8] A steep concentration-toxicity curve[9][10] means small dose increases can shift from intoxication to life-threatening delirium, and high dopamine-over-serotonin selectivity drives compulsive redosing.[11][12] No controlled human studies have been conducted — the evidence base rests on animal pharmacology, forensic case series, and emergency department reports.
History[edit]
Discovery
Ephylone was first synthesized in the 1960s at Boehringer Ingelheim in Germany as part of a program exploring cathinone analogs as treatments for depression and fatigue.[2] The compound appears in US Patent No. 3,478,050 (Koeppe, Ludwig, and Zeile, 1969), alongside related cathinones including pentylone and butylone. Early animal testing confirmed stimulant activity, but ephylone was never advanced to clinical trials or marketed as a pharmaceutical.[3]
Emergence on illicit markets
Ephylone first appeared on illicit drug markets in the United States in 2014.[2] By 2017 it had become the single most commonly seized synthetic cathinone in the country, accounting for more than half of all identifications.[3] A consistent pattern was the sale of ephylone as counterfeit MDMA in tablet or powder form — a particularly dangerous practice, as users expecting MDMA doses would unknowingly consume ephylone at levels far exceeding its active range.[10][2]
Regulatory response
The rapid accumulation of fatalities prompted emergency scheduling. The US Drug Enforcement Administration temporarily placed ephylone in Schedule I on August 31, 2018, citing 151 overdose deaths since 2015;[8] permanent Schedule I placement followed in June 2021.[5] Internationally, the WHO Expert Committee on Drug Dependence recommended Schedule II placement under the 1971 Convention on Psychotropic Substances in 2018.[4]
The name "ephylone" follows the informal convention for synthetic cathinones: the "e" prefix denotes the N-ethyl substitution that distinguishes it from pentylone (N-methyl). Alternative designations include bk-EBDP (beta-keto-ethylbenzodioxolylpentanamine) and N-ethylnorpentylone, the latter used in WHO and DEA scheduling documents. None of these names have penetrated popular culture — ephylone's notoriety rests almost entirely on its role as an undetected MDMA adulterant rather than a substance sought by name.
Chemistry[edit]
Structural class
Ephylone belongs to the substituted cathinone family — synthetic analogs of cathinone, the principal psychoactive alkaloid of the khat plant (Catha edulis). It is simultaneously a methylenedioxy phenethylamine by virtue of its 3,4-methylenedioxy (benzodioxole) ring, which gives it partial structural resemblance to MDMA and methylone.[14]
Ephylone is distinguished from its close analog pentylone by an N-ethyl rather than N-methyl group on the amine nitrogen. The elongated α-propyl chain and N-ethyl group shift its pharmacological profile away from the MDMA-like releaser category toward the reuptake-inhibitor profile characteristic of pyrovalerone-type cathinones.[14]
Molecular properties
| Molecular formula | C₁₄H₁₉NO₃ |
| Molecular weight | 249.30 g/mol |
The moderate lipophilicity of ephylone is consistent with adequate oral absorption and blood-brain barrier penetration.
Stereochemistry
Ephylone possesses one chirality center at C-2, giving rise to R and S enantiomers. The compound circulating on recreational markets is invariably the racemic mixture.[2] No published data compare the pharmacological activity of individual ephylone enantiomers, though enantioselective potency differences are known in structurally related cathinones.[11]
Physical properties
The hydrochloride salt has been structurally characterized by X-ray crystallography.[15] On illicit markets, ephylone has been encountered as powder, crystal, rock, capsule, or tablet.[2] Melting point, solubility, and storage stability have not been systematically reported.
Pharmacology[edit]
Mechanism of action
Ephylone blocks the reuptake of all three major monoamine neurotransmitters — dopamine, norepinephrine, and serotonin — by binding to their respective transporters.[1] It does not cause the transporters to release stored neurotransmitter, a distinction that separates it from MDMA and methylone and places it in the same pharmacological category as cocaine and MDPV.[16][17]
The compound binds most strongly to the DAT, with roughly ten-fold weaker affinity for the SERT.[1] This dopamine-dominant profile predicts strong reinforcement and high abuse potential.[11] Compounds with this selectivity pattern are associated with prolonged stimulation, insomnia, agitation, and psychotic symptoms at higher doses.[12]
The methylenedioxy ring gives ephylone modestly higher serotonin transporter affinity compared to purely pyrrolidine-type cathinones.[14] This residual serotonergic component likely accounts for the mild empathogenic quality some users report, though the absence of serotonin release limits this effect compared to MDMA-type compounds.
Pharmacokinetics
No controlled human pharmacokinetic studies have been published. Oral onset is reported at 15–30 minutes, with a total subjective duration of 4–8 hours and aftereffects lasting 6–24 hours; these values derive from community consensus and lack clinical confirmation.safety citation needed
In vitro studies using human liver microsomes have identified four principal metabolic pathways: N-dealkylation, reduction of the beta-keto group, opening of the methylenedioxy ring, and glucuronide conjugation.[18] Four metabolites were also identified in a fatal intoxication case.[9] The specific liver enzymes responsible have not been identified, though involvement of CYP2D6, CYP3A4, and CYP1A2 is plausible based on structural analogy with related cathinones.inferred
Metabolites of the methylenedioxy cathinone class can retain activity at monoamine systems, potentially contributing to the extended duration of effects.[19] Blood-brain barrier penetration has been studied in rats, with transport appearing carrier-mediated, analogous to cocaine.[20]
Neuroscience[edit]
Where it acts
Ephylone's dominant neural effect is potentiation of dopamine signaling in the mesolimbic mesolimbic pathway — the projection from the ventral tegmental area to the nucleus accumbens — which underlies its euphoric and reinforcing properties.[11] Chronic exposure produces robust accumulation of ΔFosB in the striatum,[6] a molecular marker that drives the transition from voluntary to compulsive drug-seeking by altering gene expression in reward-circuit neurons.
Withdrawal following repeated exposure produces measurable depletion of serotonin and norepinephrine in the striatum and prefrontal cortex, accompanied by elevated stress hormones.[6] These changes correlate with depressive behavior, increased aggression, and paradoxical hyperactivity in mice. Sex differences are documented: females self-administer more at higher doses, while males are more vulnerable to dangerous overheating.[21]
Why it matters
Ephylone's pharmacology is best understood through the incentive salience framework — the distinction between "wanting" and "liking." The strong dopamine-over-serotonin selectivity predicts that ephylone disproportionately drives motivation to obtain the drug relative to actual subjective pleasure.[12] This pattern predicts escalating compulsive use despite diminishing enjoyment — a hallmark of addiction.[7]
Repeated exposure also produces locomotor sensitization in mice,[6] indicating lasting neuroplastic changes in reward circuits similar to those produced by cocaine and amphetamine.
Whether ephylone produces lasting neurotoxicity — as opposed to reversible adaptation — remains unknown. Serotonin depletion observed during withdrawal in mice[6] could reflect either temporary downregulation or permanent damage to serotonergic terminals, a distinction with major implications for long-term users. The broader cathinone class is associated with neurotoxic potential,[22] but ephylone-specific data are absent.
Subjective Effects[edit]
Ephylone produces an experience shaped by a fundamental tension in its pharmacology: potent dopamine reuptake inhibitor drives stimulation and reward, while moderate serotonin inhibition adds a thin empathogenic layer that users frequently liken to MDMA but which lacks the serotonin-releasing mechanism behind MDMA's emotional depth. At lower doses the serotonergic warmth is more noticeable; at higher doses or with repeated administration the experience tilts sharply toward pure stimulation — energy, focus, restlessness — as dopaminergic effects dominate. Set and setting strongly influence whether the serotonergic component registers as prosocial warmth or anxious hyperarousal.
Pharmacologically, ephylone occupies a middle ground between MDMA and MDPV: it shares the methylenedioxy ring of entactogens but operates through the reuptake-inhibitor mechanism of pyrovalerone-type stimulants. Users familiar with MDMA should expect a more stimulant-dominant, less emotionally rich experience with substantially higher compulsive redosing potential.[3]
Effect Grid
Clear stimulation with pronounced cognitive euphoria and sustained wakefulness. Focus enhancement and motivation enhancement are noticeable. Some users report empathogenic warmth and emotional enhancement, though the pharmacological profile (pure reuptake inhibition, no serotonin release) predicts a more stimulant-dominant experience than MDMA.
Bruxism and muscle tension become apparent. Heart rate and blood pressure are elevated. Appetite suppression is marked, and excessive sweating and temperature dysregulation may emerge. The compulsive redosing urge — a defining feature of ephylone's DAT-selective profile — becomes a significant factor at this tier.
Insomnia is likely for 6+ hours post-dose. Aftereffects include depressed mood, irritability, and fatigue lasting 6–24 hours.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Color enhancement
Physical fatigue · Wakefulness · Dry mouth · Heart rate perception changes · Pupil dilation · Restlessness · Tactile euphoria · Bruxism · Dehydration sensation · Excessive sweating · Muscle tension · Respiratory stimulation · Spontaneous body sensations · Tingling / electric sensations · Bodily lightness · Dizziness · Headache · Laughter fits · Nausea · Nystagmus (eye wobbles) · Sexual arousal enhancement · Vibrations / buzzing · Trembling · Vomiting
Pupil dilation · Restlessness · Tactile euphoria · Bruxism · Dehydration sensation · Excessive sweating · Muscle tension · Respiratory stimulation · Spontaneous body sensations · Tingling / electric sensations · Bodily lightness · Dizziness · Headache · Laughter fits · Nausea · Nystagmus (eye wobbles) · Sexual arousal enhancement · Vibrations / buzzing · Trembling · Vomiting
Aesthetic enhancement · Openness enhancement · Motivation enhancement · Cognitive dysphoria · Cognitive flexibility · Focus enhancement · Immersion enhancement · Information processing enhancement · Introspection enhancement · Novelty enhancement · Pattern recognition enhancement · Suggestibility enhancement · Thought connectivity · Analysis enhancement · Creativity enhancement · Humor enhancement · Language enhancement · Confusion · Memory fragmentation · Thought disorganization · Thought loops
Cognitive dysphoria · Cognitive flexibility · Focus enhancement · Immersion enhancement · Information processing enhancement · Introspection enhancement · Novelty enhancement · Pattern recognition enhancement · Thought connectivity · Analysis enhancement · Creativity enhancement · Humor enhancement · Language enhancement · Confusion · Memory fragmentation · Thought disorganization · Thought loops
Empathy enhancement · Anhedonia · Anxiety suppression · Emotional lability · Irritability · Catharsis · Dysphoria · Simultaneous emotions
Irritability · Catharsis · Dysphoria · Simultaneous emotions
Communication enhancement · Sociability enhancement · Emotional susceptibility · Trust enhancement · Flow state · Boundary dissolution
Flow state · Boundary dissolution
Timeline
Initial alertness and subtle mood shift emerge. Slight sympathomimetic activation — faint heart rate awareness — signals the compound's arrival.
Building stimulation and cognitive euphoria. Heart rate increases noticeably. Appetite suppression sets in and sociability begins to rise.
Maximum stimulation, euphoria, and wakefulness. Bruxism, sweating, and temperature dysregulation are most prominent. Compulsive redosing urge is strongest during this phase.
Stimulation persists but euphoria gradually fades. Irritability and dysphoria begin to emerge. Residual wakefulness continues despite declining subjective reward.
Stimulation recedes toward baseline. Fatigue, depressed mood, and irritability intensify. Physical discomfort — jaw soreness, muscle tension — becomes more noticeable as stimulation withdraws.
Residual insomnia, depressed mood, cognitive fatigue, appetite suppression, and irritability persist well beyond the subjective experience. This is not a positive afterglow but a stimulant aftermath.
⚠ Do not drive or operate heavy machinery for at least 12 hours after last dose — stimulant aftereffects impair reaction time and judgment even after subjective effects have diminished.
Safety[edit]
- Acute toxicity
- High
- Chronic toxicity
- Moderate
- Withdrawal
- Moderate
- Tolerance buildup
- moderate
- Tolerance reset
- —
- Physical
- Moderate
- Psychological
- High
- Compulsive redosing
- High
- Dose escalation
- High
- Cross-tol.
- cocaine · amphetamine · MDPV
Toxicity
Acute toxicity
Ephylone has caused a significant number of deaths relative to its period of availability. The US DEA linked the compound to 151 overdose deaths between 2015 and August 2018.[8] The mouse LD₅₀ is 240 mg/kg (route unspecified).[2]safety citation needed No human lethal dose has been established, and no controlled dose-finding studies exist.
Postmortem blood concentrations in fatal cases range widely (0.01–10.6 mg/L),[9][10] while clinical intoxication cases present at much lower levels (7–170 ng/mL).[1] This gap suggests a steep concentration-toxicity curve, though direct comparison is complicated by post-death redistribution.
Adverse effects
Documented adverse effects include[23][1][10][22]:
- Heart and circulation: rapid heartbeat, high blood pressure, irregular heartbeat
- Brain and nervous system: hallucinations, agitation, confusion, excited delirium, seizures, coma
- Metabolic: dangerous overheating, muscle breakdown, metabolic acidosis
- Kidneys: acute kidney injury secondary to muscle breakdown
- Fatal: multi-organ failure
Excited delirium
Ephylone is disproportionately associated with excited delirium — a state of dangerous agitation, overheating, and cardiovascular collapse.[10][1] Both postmortem case series and clinical reports identify this as a characteristic toxicity pattern. Whether this reflects a unique pharmacological property or simply higher exposure levels from MDMA substitution is unresolved.
Overheating
Dangerous body temperature elevation is documented in both animal studies and human cases. Male animals show greater vulnerability to overheating than females.[21]
Psychological risks
No controlled studies of ephylone's psychological effects exist. In UK emergency department presentations, hallucinations occurred in 44% of cases (4/9), with agitation and confusion each present in 67%.[23]
The dopamine-dominant pharmacology carries significant risk for stimulant psychosis (paranoia, delusions, and hallucinations from excessive dopamine stimulation),[12] agitated delirium with risk of self-harm and exhaustion, post-use depression from monoamine depletion,[6] and increased aggression during withdrawal.[6]
Tolerance and dependence
Animal models consistently indicate high dependence potential. Ephylone fully substitutes for both methamphetamine and cocaine in drug discrimination tests — the strongest preclinical indicator of stimulant abuse potential.[2] Chronic exposure produces robust ΔFosB elevation in the striatum, a molecular marker of the transition from recreational to compulsive use.[6]
In zebrafish models, ephylone showed the highest abuse liability among methylenedioxy cathinones tested, with conditioned preference that persisted through extinction and reinstated after two weeks of abstinence.[7] Female mice self-administer ephylone at greater rates than males at higher doses.[21]
Withdrawal in mice produces serotonin and norepinephrine depletion in the brain, depressive behavior, increased aggression, hyperactivity, and elevated stress hormones.[6] No human withdrawal studies have been published.
Tolerance development has not been directly quantified for ephylone. Development of tolerance with prolonged use is consistent with general cathinone class properties but remains unverified for this compound.inferred
Drug interactions
Serotonin toxicity. Combination with serotonergic drugs — including SSRIs, SNRIs, monoamine oxidase inhibitors, triptans, tramadol, linezolid, and lithium — carries risk of serotonin syndrome via additive serotonergic effects.[22] The interaction with tramadol is classified as lethal; this is pharmacologically plausible but has not been verified by a published case report.safety citation needed
Cardiovascular overload. Combination with other stimulants (MDMA, amphetamines, cocaine), sympathomimetics, or drugs that prolong the QT interval carries additive cardiovascular risk — rapid heartbeat, high blood pressure, irregular heartbeat, and dangerous overheating.[24][25] The MDMA interaction is classified as dangerous; this is pharmacologically plausible but unverified by published case report.safety citation needed
The interaction with alcohol is listed as unknown. No published data on the ephylone-alcohol combination were identified.
Contraindications
No clinical guidelines specific to ephylone have been published. The following are inferred from its pharmacological mechanism and the general cathinone class safety profileinferred:
- MAO inhibitors (absolute) — risk of dangerously high blood pressure and serotonin toxicity
- Pre-existing heart conditions (absolute) — ephylone's stimulant activity produces rapid heartbeat, high blood pressure, and irregular heartbeat that may be fatal in people with structural heart disease or conduction abnormalities
- Seizure disorders (relative) — stimulant cathinones lower seizure threshold[22]
- Liver impairment (relative) — ephylone undergoes liver metabolism via multiple pathways;[18] impaired metabolism may increase exposure and toxicity risk
- Concurrent serotonergic medication (relative) — SSRIs, SNRIs, triptans, and other serotonergic drugs increase serotonin syndrome risk
- Hot environments and physical exertion (relative) — dehydration, heat, and vigorous activity potentiate overheating documented in animal models[21]
- Pregnancy and breastfeeding (absolute) — no reproductive toxicity data exist; exposure cannot be considered safe
Harm Reduction[edit]
Forms & Identification
Ephylone is most dangerous when it arrives unannounced — sold as MDMA or another substance without the buyer's knowledge. Reagent testing is essential but has limits: the methylenedioxy ring means ephylone produces color reactions similar to MDMA with Marquis and Mecke reagents, making visual distinction difficult. A combination of reagent kits narrows the possibilities, but only laboratory-grade analysis (GC-MS, FTIR) or drug checking services can confirm identity with certainty.
The wide range of physical forms — powder, crystal, rock, capsule, and tablet — means no visual inspection can rule ephylone out. If a substance marketed as MDMA produces unexpectedly stimulating, restless, or prolonged effects, ephylone or a similar cathinone should be suspected.
Guidelines
- Test every substance before use — reagent kits as a minimum, drug checking services where available.
- Start with the lowest plausible dose and wait at least 90 minutes before considering redosing. Onset can be delayed and stacking doses is a primary risk factor for toxicity.
- Designate a sober sitter who knows what was taken and when.
- Stay cool and hydrated — avoid hot environments, vigorous dancing, and layered clothing. Sip water steadily but do not overhydrate.
- Do not redose in pursuit of fading effects. The dopamine-dominant profile makes the compulsive redosing urge strong, but each additional dose increases cardiovascular and overheating risk without proportionally increasing desired effects.
- Set a hard limit on total dose and number of redoses before the session begins, and give the remaining supply to the sitter.
Set & Setting
Ephylone's high dopamine activity makes it particularly sensitive to environment. Overstimulating settings — loud music, crowds, heat — can tip the experience from energized into anxious or agitated. A controlled, cool environment reduces the risk of overheating and escalating agitation.
The compulsive redosing pattern driven by ephylone's pharmacology is strongest in social settings where repeated dosing feels normalized. Having a sober companion who can track time since last dose is one of the most effective single interventions.
Aftercare & integration. The comedown from ephylone can be prolonged and uncomfortable — monoamine depletion produces low mood, irritability, fatigue, and difficulty sleeping that may persist for days. Prioritize sleep, even if it requires a dark, quiet room and melatonin. Eat calorie-dense, nutritious food even if appetite is absent.
Avoid using other stimulants, caffeine, or additional ephylone to manage the comedown — this extends the depletion cycle. Physical activity at low intensity (walking, stretching) can help restore mood baseline faster than bed rest. If low mood, aggression, or anxiety persists beyond a week, consult a medical professional.
Recovery & Support
Ephylone's pharmacological profile — strong dopamine reuptake inhibitor, robust ΔFosB accumulation, and persistent conditioned reward — places it among the synthetic cathinones with highest compulsive use potential. Recognizing a pattern of escalating use, inability to limit redosing, or continued use despite negative consequences is the first step.
Stimulant-specific support resources include SAMHSA's National Helpline (1-800-662-4357, US), SMART Recovery, and local addiction services. No ephylone-specific treatment protocols exist, but standard approaches for stimulant use disorders — cognitive behavioral therapy, contingency management, and peer support — are applicable. Medical supervision during withdrawal is advisable given the documented neurochemical disruption.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency
The following signs indicate an immediate medical emergency: chest pain or irregular heartbeat; seizures; loss of consciousness or inability to respond; body temperature hot enough to feel through clothing; severe confusion, aggression, or agitation that cannot be de-escalated; muscle rigidity. Excited delirium — extreme agitation, overheating, and incoherence — is the characteristic life-threatening emergency with ephylone.
Immediate steps
- Call emergency services immediately if any of the above signs are present.
- Move the person to a cool, quiet area.
- Remove excess clothing and apply cool (not ice-cold) water to the neck, armpits, and groin to reduce body temperature.
- Place an unconscious person in the recovery position (on their side, airway clear).
- Do not restrain a severely agitated person unless there is immediate danger of self-harm — restraint can worsen overheating and cardiovascular stress.
- Stay with the person until help arrives.
What to tell the dispatcher
State the substance name (ephylone, N-ethylpentylone, or "a synthetic cathinone"), the approximate amount and time taken, and current symptoms. Good Samaritan laws in many jurisdictions protect people who call for help during a drug emergency.
Legal Status[edit]
Ephylone is controlled in multiple jurisdictions, though the scope and scheduling classification vary. The WHO Expert Committee on Drug Dependence recommended placement in Schedule II of the 1971 Convention on Psychotropic Substances following its 41st meeting in 2018, noting the absence of therapeutic use and citing 125 international toxicological reports.[4] Several individual nations have adopted stricter controls than the WHO recommendation.
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Schedule I (Controlled Substances Act) | Temporary placement August 31, 2018, citing 151 deaths since 2015;[8] permanent Schedule I effective June 14, 2021.[5] |
| United Kingdom | Controlled under Psychoactive Substances Act 2016 | Blanket ban on non-exempted psychoactive substances; not individually scheduled under the Misuse of Drugs Act 1971. |
| Netherlands | Opium List II | Added July 1, 2025.citation needed |
| Taiwan | Controlled drug | Controlled since December 2017.[2] |
| Australia | Likely Schedule 9 (Prohibited Substance) | Covered under broad cathinone provisions of the Poisons Standard; specific scheduling date not confirmed.citation needed |
| Canada | Not specifically confirmed as of 2024 | Health Canada 2024 NPS report did not specifically list ephylone; may be captured under analog provisions.citation needed |
| International (WHO/UN) | Schedule II (1971 Convention on Psychotropic Substances) | Recommended by ECDD 41st meeting, 2018.[4] |
The distinction between the WHO's Schedule II recommendation and individual nations' scheduling decisions is noteworthy: Schedule II under the 1971 Convention permits limited medical and scientific use under license, while US Schedule I prohibits all use including research without DEA authorization.
references
- [1]
- [2]
- [3]
- [4]
- [5]
- [6] ^abcdefghiEspinosa-Velasco M, Reguilón MD, Bellot M, Nadal-Gratacós N, Berzosa X, Puigseslloses P, Gómez-Canela C, Rodríguez-Arias M, Pubill D, Camarasa J, Escubedo E, López-Arnau R (2022) Behavioural and neurochemical effects after repeated administration of N-ethylpentylone (ephylone) in mice. — Journal of Neurochemistry doi:10.1111/jnc.15542